DIASORIN CONFIRMS EFFECTIVENESS OF ITS MOLECULAR DIAGNOSTIC TESTS IN LIGHT OF NEW OMICRON SARS-COV-2 VARIANT

Saluggia, Italy, November 30, 2021 - DiaSorin (FTSE MIB: DIA) confirms effectiveness of its molecular diagnostic test portfolio in light of the new Omicron SARS-CoV-2 variant B.1.1.529, now classified as Variant Under Monitoring GR/484A.

The new variant was first detected in Botswana/Hong Kong/ South Africa, and the sequences of this variant as available in GISAID database have been used for in silico analysis of all DiaSorin tests to detect SARS-CoV-2: Simplexa™ COVID-19 Direct kit, ARIES® SARS-CoV-2 Assay and Simplexa™ COVID-19 & Flu A/B Direct kit. These analyses confirmed that all assays remain accurate in detecting SARS-CoV-2.

DiaSorin continues to closely monitor the SARS-CoV-2 variants, analyzing all of the sequences that are deposited daily in the databases (NCBI and GISAID EpiCoV™ databases). The primers and probes of its molecular diagnostic assays are checked against these databases to evaluate any mutations that might influence their effectiveness. Due to the design of the primers and probes utilized in the DiaSorin assays, none of the variants, including Omicron, have impacted the performance of the assays.

DiaSorin’s monitoring approach allows an additional level of confidence for worldwide customers.

For additional information, please contact:

Riccardo Fava  
Corporate Vice President Communication & Investor Relations  
Tel: +39.0161.487988  
riccardo.fava@diasorin.it

Emanuela Salvini  
Investor Relations  
Tel: +39.0161.487567  
emanuela.salvini@diasorin.it

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide. The Group operates in 5 continents through 45 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”. More info at www.diasoringroup.com